



KINEXUS

Kinexus Introduces New Apoptosis Protein Profiling Service

Kinetworks™ Screening Service Designed to Improve Discovery-Based Research

FOR IMMEDIATE RELEASE JULY 1, 2002

VANCOUVER, British Columbia - Kinexus Bioinformatics Corporation is pleased to announce today the launch of its fifth proteomics screen called Kinetworks™ Apoptosis Protein Screen (KAPS) 1.0. This screen tracks 25 caspases and other apoptosis-related proteins with high accuracy, precision, speed and reproducibility on a single gel. Research in the area of programmed cell death has been an important focus of researchers since defective signalling through apoptotic pathways contributes to fatal diseases such as cancer, heart disease, Parkinson's and AIDS. The Kinetworks™ Apoptosis Screen is complementary to the other protein profiling services offered by Kinexus, specifically tracking more than 183 cell signalling proteins. Each screen is organized within thematic families of protein kinases (KPKS), protein phosphatases (KPPS), phosphoproteins (KPSS), and stress/heat shock proteins (KHSP). Sample preparation instructions, service agreement and order forms are available online at www.kinexus.ca.

"We are proud to offer this service, which to our knowledge, is the first commercially available screen specifically targeting most of the known caspases" reported Dr. Steven Pelech, President and Chief Scientific Officer of Kinexus, and a Professor in the Department of Medicine at the University of British Columbia. "It is a cost-effective solution to identify apoptotic proteins that may be relevant in different model systems and in different disease states. All of the Kinetworks™ screens are reliable, robust, highly sensitive, and utilize proprietary technologies designed to mitigate the risk while maximizing prospects in discovery-based research."

"The Kinetworks™ commercial division has experienced a steady sales growth since last year, with a 90% increase in revenue for this quarter as compared to last quarter," said Mr. David Turner, Chief Executive Officer of Kinexus. "We are very excited about the potential of the apoptosis screen and are nearing completion on a cell cycle protein screen to be released later this year."

Kinexus specializes in providing innovative proteomic solutions to industrial and academic clients using standardized immunoblotting screens. Client benefits include the identification of disease markers and drugable targets, characterization of drug leads and validation of appropriate animal markers of human disease. The future application of this knowledge will facilitate disease diagnosis and personalized therapies to improve human health.

For further information, please contact Kinexus Bioinformatics Corporation toll free at 1-866-KINEXUS or visit our website at www.kinexus.ca.

PRESS RELEASE - 2002 JULY 1

